封面
市場調查報告書
商品編碼
1705643

全球痙攣性截癱 50 市場(按治療類型、給藥途徑、最終用戶和地區分類)

Global Spastic Paraplegia 50 Market, By Treatment Type, By Route of Administration, By End User, By Geography

出版日期: | 出版商: Coherent Market Insights | 英文 165 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2025 年全球痙攣性截癱 50 市場規模估計為 1.303 億美元,預計到 2032 年將達到 2.637 億美元,2025 年至 2032 年的複合年成長率為 10.6%。

報告範圍 報告詳細資訊
基準年 2024 2025年的市場規模 1.303億美元
效能數據 從2020年到2024年 預測期 2025年至2032年
預測期:2025-2032年複合年成長率: 10.60% 2032年價值預測 2.637億美元
數字。 2025年痙攣性截癱50型藥物全球市場佔有率(按地區)
全球痙攣性截癱 50 市場-IMG1

痙攣性截癱 50(SPG50)是一種罕見的遺傳性神經系統疾病,其特徵是下肢痙攣和無力。它是由 CYTH4 基因突變引起的,該基因編碼細胞週期蛋白 4,對中樞神經系統的軸突髓鞘形成至關重要。缺乏適當的髓鞘形成會影響大腦和下肢之間的運動神經訊號,導致僵硬和運動受損。目前尚無針對 SPG50 的核准治療方法,但基因和細胞療法的研究和開發有望在未來恢復髓鞘形成。

市場動態:

全球痙攣性截癱 50 市場受到罕見遺傳病患病率上升、對罕見適應症認知不斷提高以及開發新治療方法研發力度活性化的推動。然而,開發罕見疾病藥物的高成本構成了重大挑戰。此外,監管核准時間長、病患數量少等市場限制因素也影響了產品的商業性可行性。儘管如此,政府以研究津貼、藥品開發商稅收優惠以及孤兒藥指定等項目形式增加的支持為擴大該領域的投資提供了機會。

本研究的主要特點

  • 本報告對全球痙攣性截癱 50 市場進行了詳細分析,並提供了預測期(2025-2032 年)的市場規模和年複合成長率(CAGR),假設 2024 年為基準年。
  • 它還強調了各個領域的潛在商機,並說明了該市場的有吸引力的投資提案矩陣。
  • 它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的重要見解。
  • 它根據公司亮點、產品系列、關鍵亮點、業績和策略等參數,對全球痙攣性截癱 50 市場中的主要企業進行了概述。
  • 本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、新興趨勢、市場擴張和行銷策略做出明智的決策。
  • 全球痙攣性截癱 50 市場報告迎合了該行業的各個相關人員,例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
  • 相關人員將透過用於分析全球痙攣性截癱 50 市場的各種策略矩陣更輕鬆地做出決策。

目錄

第1章 調查目的與前提條件

  • 研究目標
  • 先決條件
  • 簡稱

第2章 市場展望

  • 報告描述
    • 市場定義和範圍
  • 執行摘要
  • Coherent Opportunity Map(COM)

第3章市場動態、法規與趨勢分析

  • 市場動態
  • 主要亮點
  • 監管情景
  • 近期動態
  • PEST分析
  • 波特分析
  • 管道概述
  • 市場參與企業的投資情景
  • 合併、收購和合作

第4章 全球痙攣性截癱市場-冠狀病毒(COVID-19)大流行的影響

  • COVID-19流行病學
  • 經濟影響

5. 全球痙攣性截癱 50 市場(依治療類型),2020 年至 2032 年

  • 藥品
  • 物理治療
  • 外科手術
  • 輔助器具
  • 其他

6. 全球痙攣性截癱 50 市場(依給藥途徑),2020 年至 2032 年

  • 口服
  • 注射
  • 局部的
  • 其他

7. 全球痙攣性截癱 50 市場(依最終使用者分類),2020 年至 2032 年

  • 醫院和診所
  • 復健中心
  • 居家照護環境

8. 2020 年至 2032 年按地區分類的全球痙攣性截癱 50 市場

  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東
  • 非洲

第9章 競爭態勢

  • 公司簡介
    • Pfizer
    • Sanofi
    • Novartis
    • GlaxoSmithKline
    • Johnson &Johnson
    • Merck
    • AstraZeneca
    • Bayer
    • Boehringer Ingelheim
    • Amgen
    • Biogen
    • Takeda Pharmaceutical
    • AbbVie
    • Bristol-Myers Squibb
    • Astellas Pharma
    • Daiichi Sankyo
    • Eisai
    • Eli Lilly
    • Gilead Sciences
    • Novo Nordisk

第 10 章 章節

  • 參考
  • 調查方法
  • 關於出版商
簡介目錄
Product Code: CMI6670

Global Spastic Paraplegia 50 Market is estimated to be valued at USD 130.3 Mn in 2025 and is expected to reach USD 263.7 Mn by 2032, growing at a compound annual growth rate (CAGR) of 10.6% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 130.3 Mn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 10.60% 2032 Value Projection: USD 263.7 Mn
Figure. Global Spastic Paraplegia 50 Market Share (%), By Region 2025
Global Spastic Paraplegia 50 Market - IMG1

Spastic Paraplegia 50 (SPG50) is a rare genetic neurological disorder characterized by lower limb spasticity and weakness. It is caused by mutations in the CYTH4 gene, which encodes the cylicin-4 protein essential for myelination of axons in the central nervous system. Lack of proper myelination affects motor nerve signals between the brain and lower limbs, resulting in stiffness and impaired mobility. Currently, there is no approved treatment for SPG50; however, research into the development of gene and cell therapies holds promise to restore myelination in the future.

Market Dynamics:

The global spastic paraplegia 50 market is driven by the rising prevalence of rare genetic disorders, growing awareness about orphan indications, and increasing research focus on developing novel treatments. However, the high costs associated with orphan drug development pose a major challenge. The market also faces restraints from long regulatory approval timelines and a small patient pool, affecting the commercial viability of products. Nonetheless, increasing government support in the form of research grants, tax incentives for drug developers, and designation programs such as orphan drug status present lucrative opportunities for greater investment in this space.

Key features of the study:

  • This report provides in-depth analysis of the global spastic paraplegia 50 market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2025-2032), considering 2024 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global spastic paraplegia 50 market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Pfizer, Sanofi, Novartis, GlaxoSmithKline, Johnson & Johnson, Merck, AstraZeneca, Bayer, Boehringer Ingelheim, Amgen, Biogen, Takeda Pharmaceutical, AbbVie, Bristol-Myers Squibb, Astellas Pharma, Daiichi Sankyo, Eisai, Eli Lilly, Gilead Sciences, and Novo Nordisk.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • Global spastic paraplegia 50 market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global spastic paraplegia 50 market.

Detailed Segmentation:

  • Global Spastic Paraplegia 50 Market, By Treatment Type
    • Medication
    • Physiotherapy
    • Surgery
    • Assistive Devices
    • Others
  • Global Spastic Paraplegia 50 Market, By Route of Administration
    • Oral
    • Injectable
    • Topical
    • Others
  • Global Spastic Paraplegia 50 Market, By End User
    • Hospitals & Clinics
    • Rehab Centers
    • Home Care Settings
  • Global Spastic Paraplegia 50 Market, By Region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Company Profiles
    • Pfizer
    • Sanofi
    • Novartis
    • GlaxoSmithKline
    • Johnson & Johnson
    • Merck
    • AstraZeneca
    • Bayer
    • Boehringer Ingelheim
    • Amgen
    • Biogen
    • Takeda Pharmaceutical
    • AbbVie
    • Bristol-Myers Squibb
    • Astellas Pharma
    • Daiichi Sankyo
    • Eisai
    • Eli Lilly
    • Gilead Sciences
    • Novo Nordisk

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Spastic Paraplegia 50 Market, By Treatment Type
    • Spastic Paraplegia 50 Market, By Route Of Administration
    • Spastic Paraplegia 50 Market, By End User
    • Spastic Paraplegia 50 Market, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restrains
    • Opportunities
  • Key Highlights
  • Regulatory Scenario
  • Recent Trends
  • PEST Analysis
  • PORTER's Analysis
  • Pipeline Overview
  • Investment Scenario by Market Players
  • Mergers, Acquisitions, and Collaborations

4. Global Spastic Paraplegia 50 Market- Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Economic Impact

5. Global Spastic Paraplegia 50 Market, By Treatment Type, 2020-2032, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Medication
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
  • Physiotherapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
  • Surgery
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
  • Assistive Devices
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

6. Global Spastic Paraplegia 50 Market, By Route Of Administration, 2020-2032, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
  • Injectable
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
  • Topical
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

7. Global Spastic Paraplegia 50 Market, By End User, 2020-2032, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospitals & Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
  • Rehab Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
  • Home Care Settings
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

8. Global Spastic Paraplegia 50 Market, By Region, 2020-2032, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, For Region, 2020 -2032
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
      • U.S.
      • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032,(US$ Mn)
      • North Africa
      • Central Africa
      • South Africa

9. Competitive Landscape

  • Company Profile
    • Pfizer
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
    • Sanofi
    • Novartis
    • GlaxoSmithKline
    • Johnson & Johnson
    • Merck
    • AstraZeneca
    • Bayer
    • Boehringer Ingelheim
    • Amgen
    • Biogen
    • Takeda Pharmaceutical
    • AbbVie
    • Bristol-Myers Squibb
    • Astellas Pharma
    • Daiichi Sankyo
    • Eisai
    • Eli Lilly
    • Gilead Sciences
    • Novo Nordisk
  • Analyst Views

10. Section

  • References
  • Research Methodology
  • About us